{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:50:57Z","timestamp":1791928257066,"version":"4.3.4"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116432","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:58:07Z","timestamp":1772038687000},"page":"116432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["NLRP3 inflammasome as a therapeutic target in oral squamous cell carcinoma: implications for tumorigenesis and immunomodulation"],"prefix":"10.1016","volume":"175","author":[{"given":"Nasim","family":"Ghasemzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Tabasom","family":"Nejati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia Sadat","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahand","family":"Emrahoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahand Saeidpour","family":"Masouleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diba","family":"Safarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahryar","family":"Irannejadrankouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin Khazeei","family":"Tabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2026.116432_bb0005","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8650","article-title":"Emerging histological and serological biomarkers in oral squamous cell carcinoma: applications in diagnosis, prognosis evaluation and personalized therapeutics (review)","volume":"50","author":"Pekarek","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2026.116432_bb0010","doi-asserted-by":"crossref","first-page":"12847","DOI":"10.1007\/s00210-025-04142-7","article-title":"Targeting ferroptosis: a novel pathway in oral, oropharyngeal, hypopharyngeal, and laryngeal cancers","volume":"398","author":"Elhami","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116432_bb0015","article-title":"Tumor microenvironment in oral squamous cell carcinoma: implications for novel therapies","volume":"12","author":"Babu","year":"2024","journal-title":"Oral Oncol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03366-y","article-title":"Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential","volume":"44","author":"Singh","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s11658-023-00462-9","article-title":"The NLRP3 inflammasome: contributions to inflammation-related diseases","volume":"28","author":"Chen","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2026.116432_bb0030","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41698-021-00154-7","article-title":"Dynamic roles of inflammasomes in inflammatory tumor microenvironment","volume":"5","author":"Jang","year":"2021","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41522-024-00511-x","article-title":"Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinoma","volume":"10","author":"Cai","year":"2024","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.intimp.2026.116432_bb0045","doi-asserted-by":"crossref","unstructured":"Scuderi SA, Casili G, Basilotta R, Lanza M, Filippone A, Raciti G, et al. NLRP3 inflammasome inhibitor BAY-117082 reduces oral squamous cell carcinoma progression. Int. J. Mol. Sci. [Internet]. 2021; 22(20).","DOI":"10.3390\/ijms222011108"},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0050","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12885-018-4403-9","article-title":"NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-025-10462-x","article-title":"Current nano drug delivery systems for targeting head and neck squamous cell carcinoma microenvironment: a narrative review","volume":"52","author":"Faraji-Barhagh","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2026.116432_bb0060","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 Inflammasome activation in Cancer: a double-edged sword","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116432_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2025.130800","article-title":"Inhibitors of inflammasome (NLRP3) signaling pathway as promising therapeutic candidates for oral cancer","volume":"1869","author":"Agrawal","year":"2025","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.intimp.2026.116432_bb0070","doi-asserted-by":"crossref","unstructured":"Wen J, Xuan B, Liu Y, Wang L, He L, Meng X, et al. NLRP3 inflammasome-induced pyroptosis in digestive system tumors. Front. Immunol. 2023;14\u20132023.","DOI":"10.3389\/fimmu.2023.1074606"},{"issue":"16","key":"10.1016\/j.intimp.2026.116432_bb0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/cells13161365","article-title":"Implication of the LRR domain in the regulation and activation of the NLRP3 inflammasome","volume":"13","author":"Cescato","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0080","article-title":"Structural basis for the oligomerization-facilitated NLRP3 activation","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0090","doi-asserted-by":"crossref","first-page":"C645","DOI":"10.1152\/ajpcell.00421.2021","article-title":"The role of Cl(-) and K(+) efflux in NLRP3 inflammasome and innate immune response activation","volume":"322","author":"Koumangoye","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.intimp.2026.116432_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.intimp.2026.116432_bb0100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 inflammasome and its inhibitors: a review","volume":"6","author":"Shao","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116432_bb0105","series-title":"NLR Proteins: Methods and Protocols","first-page":"1","article-title":"Canonical inflammasomes","author":"VNC","year":"2023"},{"issue":"13","key":"10.1016\/j.intimp.2026.116432_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116432_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00211","article-title":"NLRP3 inflammasome\u2014a key player in antiviral responses","volume":"11","author":"Zhao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116432_bb0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.abb.2019.02.008","article-title":"NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways","volume":"670","author":"Platnich","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.intimp.2026.116432_bb0125","doi-asserted-by":"crossref","first-page":"1007705","DOI":"10.3389\/fimmu.2022.1007705","article-title":"NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: from cryopyrin function to targeted therapies","volume":"13","author":"Moltrasio","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome\u2013IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier","year":"2025","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.intimp.2026.116432_bb0135","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.intimp.2026.116432_bb0140","article-title":"NLRP3 inflammasome in Alzheimer\u2019s disease: molecular mechanisms and emerging therapies","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4049\/jimmunol.2300745","article-title":"NLRP3 inflammasomes: dual function in infectious diseases","volume":"213","author":"Li","year":"2024","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14010029","article-title":"Staphylococcal enterotoxin a induces intestinal barrier dysfunction and activates NLRP3 inflammasome via NF-\u03baB\/MAPK signaling pathways in mice","volume":"14","author":"Liu","year":"2022","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.intimp.2026.116432_bb0155","doi-asserted-by":"crossref","unstructured":"Pandeya A, Zhang Y, Cui J, Yang L, Li J, Zhang G, et al. Inflammasome activation and pyroptosis mediate coagulopathy and inflammation in Salmonella systemic infection. Microbiol. Res. 2023;275:127460.","DOI":"10.1016\/j.micres.2023.127460"},{"key":"10.1016\/j.intimp.2026.116432_bb0160","doi-asserted-by":"crossref","unstructured":"Yue Z, Zhang X, Gu Y, Liu Y, Lan L-M, Liu Y, et al. Regulation and functions of the NLRP3 inflammasome in RNA virus infection. Front. Cell. Infect. Microbiol. 2024;13\u20132023.","DOI":"10.3389\/fcimb.2023.1309128"},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12272-021-01307-9","article-title":"Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases","volume":"44","author":"Seok","year":"2021","journal-title":"Arch. Pharm. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0170","article-title":"The pro-inflammatory effect of Staphylokinase contributes to community-associated Staphylococcus aureus pneumonia","volume":"5","author":"Wang","year":"2022","journal-title":"Commun. Biol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116432_bb0175","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1007\/s11033-023-08900-9","article-title":"Staphylococcus aureus enhances osteoclast differentiation and bone resorption by stimulating the NLRP3 inflammasome pathway","volume":"50","author":"Yao","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2026.116432_bb0180","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211036845","article-title":"The NLRP3 inflammasome mediates liver failure by activating procaspase-1 and pro-IL-1 \u03b2 and regulating downstream CD40-CD40L signaling","volume":"49","author":"Li","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.intimp.2026.116432_bb0185","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molimm.2020.01.011","article-title":"NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV-ACLF","volume":"120","author":"Jia","year":"2020","journal-title":"Mol. Immunol."},{"issue":"7484","key":"10.1016\/j.intimp.2026.116432_bb0190","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature12940","article-title":"Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection","volume":"505","author":"Doitsh","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2026.116432_bb0195","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116432_bb0200","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01933-y","article-title":"MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation","volume":"17","author":"Jiang","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"7","key":"10.1016\/j.intimp.2026.116432_bb0210","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bph.15732","article-title":"Time-dependent dual effect of NLRP3 inflammasome in brain ischaemia","volume":"179","author":"Palomino-Antolin","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10753-024-02036-z","article-title":"Dual regulation of nicotine on NLRP3 inflammasome in macrophages with the involvement of lysosomal destabilization, ROS and \u03b17nAChR","volume":"48","author":"Wu","year":"2025","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa345","article-title":"Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer","volume":"22","author":"Ju","year":"2021","journal-title":"Brief. Bioinform."},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0225","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210280","article-title":"Low NLRP3 expression predicts a better prognosis of colorectal cancer","volume":"41","author":"Shi","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.intimp.2026.116432_bb0230","doi-asserted-by":"crossref","unstructured":"West AJ, Deswaerte V, West AC, Gearing LJ, Tan P, Jenkins BJ. Inflammasome-associated gastric tumorigenesis is independent of the NLRP3 pattern recognition receptor. Front. Oncol. 2022;Volume 12\u20132022.","DOI":"10.3389\/fonc.2022.830350"},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0235","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.21037\/tcr-20-3135","article-title":"The role of NLRP3 in the prognosis and immune infiltrates of skin cutaneous melanoma (SKCM)","volume":"10","author":"Wu","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116432_bb0240","doi-asserted-by":"crossref","unstructured":"Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, et al. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc. Natl. Acad. Sci. U. S. A. 2021;118(10):e2000915118.","DOI":"10.1073\/pnas.2000915118"},{"key":"10.1016\/j.intimp.2026.116432_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108545","article-title":"NLRP3 and cancer: pathogenesis and therapeutic opportunities","volume":"251","author":"Tengesdal","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.116432_bb0250","doi-asserted-by":"crossref","first-page":"858","DOI":"10.21037\/tlcr-22-311","article-title":"NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma","volume":"11","author":"Gu","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.intimp.2026.116432_bb0255","article-title":"Role of the NLRP3 inflammasome: insights into Cancer hallmarks","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0260","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.immuni.2015.08.013","article-title":"The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity","volume":"43","author":"Dupaul-Chicoine","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/srep26280","article-title":"Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death","volume":"6","author":"Salaro","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116432_bb0270","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.2147\/OTT.S260793","article-title":"Downregulation of IRAK1 prevents the malignant behavior of hepatocellular carcinoma cells by blocking activation of the MAPKs\/NLRP3\/IL-1\u03b2 pathway","volume":"13","author":"Chen","year":"2020","journal-title":"Onco. Targets Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.116432_bb0275","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00018-017-2720-9","article-title":"Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"75","author":"Chen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116432_bb0280","doi-asserted-by":"crossref","DOI":"10.4103\/jcrt.JCRT_849_18","article-title":"Nod-like receptor protein 3 inflammasome in head-and-neck cancer","volume":"16","author":"Sheeja","year":"2020","journal-title":"J. Cancer Res. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.116432_bb0285","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-022-03357-4","article-title":"NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.intimp.2026.116432_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004832","article-title":"Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance","volume":"10","author":"Cheng","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116432_bb0295","doi-asserted-by":"crossref","first-page":"219","DOI":"10.34172\/joddd.2021.036","article-title":"Drug resistance against 5-fluorouracil and cisplatin in the treatment of head and neck squamous cell carcinoma: a systematic review","volume":"15","author":"Atashi","year":"2021","journal-title":"J. Dent. Res., Dent. Clin., Dent. Prosp."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0300","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13046-017-0553-x","article-title":"The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma","volume":"36","author":"Feng","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0305","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-017-0589-y","article-title":"NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma","volume":"36","author":"Huang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116432_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00588","article-title":"Correlation between the NLRP3 inflammasome and the prognosis of patients with LSCC","volume":"9","author":"Xue","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116432_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109222","article-title":"LncRNA RGMB-AS1 promotes laryngeal squamous cell carcinoma cells progression via sponging miR-22\/NLRP3 axis","volume":"118","author":"Xu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0320","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1074\/mcp.RA119.001808","article-title":"Mitochondrial oxidative phosphorylation complex regulates NLRP3 inflammasome activation and predicts patient survival in nasopharyngeal carcinoma*","volume":"19","author":"Chung","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"issue":"3","key":"10.1016\/j.intimp.2026.116432_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjorl.2025.101566","article-title":"Identification of TMEM71 as a hub NLRP3-related gene suppressing malignant behavior in nasopharyngeal carcinoma via the NLRP3\/caspase-1\/GSDMD signaling pathway","volume":"91","author":"Liu","year":"2025","journal-title":"Braz. J. Otorhinolaryngol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116432_bb0330","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1128\/JVI.00125-08","article-title":"Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3","volume":"82","author":"Kung","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2026.116432_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.640207","article-title":"The role of EBV-encoded LMP1 in the NPC tumor microenvironment: from function to therapy","volume":"11","author":"Lo","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116432_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081786","article-title":"Roles of inflammasomes in Epstein-Barr virus-associated nasopharyngeal cancer","volume":"13","author":"Looi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.intimp.2026.116432_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167352","article-title":"PLUNC inhibits invasion and metastasis in nasopharyngeal carcinoma by inhibiting NLRP3 inflammasome activation","volume":"1870","author":"Zhou","year":"2024","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0350","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12935-022-02494-1","article-title":"FERMT1 contributes to the migration and invasion of nasopharyngeal carcinoma through epithelial\u2013mesenchymal transition and cell cycle arrest","volume":"22","author":"Li","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.intimp.2026.116432_bb0355","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1002\/jcp.26331","article-title":"MicroRNA-22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3","volume":"233","author":"Feng","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116432_bb0360","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/mc.23907","article-title":"SOAT1 activates NLRP3 inflammasome to promote cancer-related lymphangiogenesis and metastasis via IL-1\u03b2\/IL-1R-1 axis in oral squamous cell carcinoma","volume":"64","author":"Zhao","year":"2025","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01720-7","article-title":"Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival","volume":"9","author":"Ye","year":"2023","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0370","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12951-021-00995-1","article-title":"Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma","volume":"19","author":"Yang","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0375","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12964-023-01235-9","article-title":"Divergent functions of NLRP3 inflammasomes in cancer: a review","volume":"21","author":"Shadab","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0380","article-title":"A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity","volume":"16","author":"Liu","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0385","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-025-02416-4","article-title":"Review: progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma","volume":"23","author":"Zhuo","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.intimp.2026.116432_bb0390","doi-asserted-by":"crossref","first-page":"1198269","DOI":"10.3389\/fimmu.2023.1198269","article-title":"The emerging role of oral microbiota in oral cancer initiation, progression and stemness","volume":"14","author":"Saikia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116432_bb0395","doi-asserted-by":"crossref","unstructured":"Yao Y, Shen X, Zhou M, Tang B. Periodontal pathogens promote oral squamous cell carcinoma by regulating ATR and NLRP3 inflammasome. Front. Oncol. 2021;11\u20132021.","DOI":"10.3389\/fonc.2021.722797"},{"issue":"6","key":"10.1016\/j.intimp.2026.116432_bb0400","doi-asserted-by":"crossref","first-page":"14094","DOI":"10.1080\/21655979.2022.2078556","article-title":"Neisseria sicca and Corynebacterium matruchotii inhibited oral squamous cell carcinomas by regulating genome stability","volume":"13","author":"Shen","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.intimp.2026.116432_bb0405","article-title":"Neutrophils promote tumor progression in oral squamous cell carcinoma by regulating EMT and JAK2\/STAT3 signaling through Chemerin","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116432_bb0410","article-title":"Effects of macrophages in OSCC progression","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116432_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166695","article-title":"Tumor-associated macrophages facilitate oral squamous cell carcinomas migration and invasion by MIF\/NLRP3\/IL-1\u03b2 circuit: a crosstalk interrupted by melatonin","volume":"1869","author":"Wang","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0420","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41420-024-01982-9","article-title":"Neutrophil extracellular traps promote invasion and metastasis via NLRP3-mediated oral squamous cell carcinoma pyroptosis inhibition","volume":"10","author":"Zhai","year":"2024","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.intimp.2026.116432_bb0425","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/odi.14161","article-title":"ALDH3A1 overexpression in OSCC inhibits inflammation via phospho-Ser727 at STAT3 in tumor-associated macrophages","volume":"29","author":"Wang","year":"2023","journal-title":"Oral Dis."},{"key":"10.1016\/j.intimp.2026.116432_bb0430","first-page":"1","article-title":"NLRP3 inflammasome-based therapies by natural products: a new development in the context of cancer therapy","author":"Owida","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0435","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12105-024-01685-8","article-title":"Unravelling the significance of NLRP3 and IL-\u03b21 in oral squamous cell carcinoma and potentially malignant oral disorders: a diagnostic and prognostic exploration","volume":"18","author":"Jain","year":"2024","journal-title":"Head Neck Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0440","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13046-022-02376-4","article-title":"Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2\/STAT3\/Sox4\/NLRP3 signaling pathway","volume":"41","author":"Xiao","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010013","article-title":"Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors","volume":"13","author":"Nelson","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.116432_bb0450","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/febs.12283","article-title":"The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases","volume":"280","author":"Krishnan","year":"2013","journal-title":"FEBS J."},{"issue":"10","key":"10.1016\/j.intimp.2026.116432_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102796","article-title":"Therapeutic potential of BAY-117082, a selective NLRP3 inflammasome inhibitor, on metastatic evolution in human oral squamous cell carcinoma (OSCC)","volume":"15","author":"Casili","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.intimp.2026.116432_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25020332","article-title":"Solubility and bioavailability enhancement of oridonin: a review","volume":"25","author":"Zhang","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2026.116432_bb0465","article-title":"Oridonin: a review of its pharmacology, pharmacokinetics and toxicity","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116432_bb0470","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5152\/eurasianjmed.2015.0267","article-title":"A review of melatonin, its receptors and drugs","volume":"48","author":"Emet","year":"2016","journal-title":"Euras. J. Med."},{"key":"10.1016\/j.intimp.2026.116432_bb0475","article-title":"Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence","volume":"42","author":"Foley","year":"2018","journal-title":"Complement. Ther. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116432_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24266","article-title":"Comprehensive review of melatonin as a promising nutritional and nutraceutical supplement","volume":"10","author":"Kamfar","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2026.116432_bb0485","doi-asserted-by":"crossref","unstructured":"Fan FS. Inhibition of NLRP3 inflammasome activation by caffeine might be a potential mechanism to reduce the risk of squamous cell carcinoma of the oral cavity and oropharynx with coffee drinking. Front. Oral Health 2022;Volume 3\u20132022.","DOI":"10.3389\/froh.2022.1017543"},{"key":"10.1016\/j.intimp.2026.116432_bb0490","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s10787-025-01739-5","article-title":"From bench to bedside: exploring curcumin-driven signaling pathways in immune cells for cancer management","volume":"33","author":"Goleij","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2026.116432_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107464","article-title":"Phytostilbenes in lymphoma: focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvin","volume":"138","author":"Goleij","year":"2024","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0500","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/ph19010060","article-title":"Innovations in the delivery of bioactive compounds for cancer prevention and therapy: advances, challenges, and future perspectives","volume":"19","author":"Ligarda-Samanez","year":"2026","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.intimp.2026.116432_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155157","article-title":"Anticancer activity of Bacopa monnieri through apoptosis induction and mitophagy-dependent NLRP3 inflammasome inhibition in oral squamous cell carcinoma","volume":"123","author":"Mishra","year":"2024","journal-title":"Phytomedicine"},{"issue":"11","key":"10.1016\/j.intimp.2026.116432_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/nu17111939","article-title":"Bacopa monnieri: preclinical and clinical evidence of neuroactive effects, safety of use and the search for improved bioavailability","volume":"17","author":"Go\u015bciniak","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2026.116432_bb0515","doi-asserted-by":"crossref","first-page":"213","DOI":"10.22159\/ijpps.2016v8i12.13488","article-title":"Optimization of bacoside A loaded snedds using d-optimal mixture design for enhancement insolubility and bioavailability","author":"Gohel","year":"2016","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.intimp.2026.116432_bb0520","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejphar.2017.09.021","article-title":"Oridonin induces G2\/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma","volume":"815","author":"Wang","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0525","article-title":"Molecular mechanisms underlying anticancer and anti-inflammatory activities of oridonin in oral squamous cell carcinoma","volume":"7","author":"Ome Kalsoom","year":"2025","journal-title":"Biosci. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2026.116432_bb0530","article-title":"Anthocyanins: metabolic digestion, bioavailability, therapeutic effects, current pharmaceutical\/industrial use, and innovation potential","volume":"12","author":"Ayvaz","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.intimp.2026.116432_bb0535","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.phymed.2018.09.223","article-title":"Anthocyanin is involved in the activation of pyroptosis in oral squamous cell carcinoma","volume":"56","author":"Yue","year":"2019","journal-title":"Phytomedicine"},{"issue":"12_Supplement","key":"10.1016\/j.intimp.2026.116432_bb0540","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1158\/1538-7445.AM2022-4222","article-title":"Abstract 4222: Phenstatin based indole linked chalcone compound 9a exhibits anti-oral cancer activity through regulating NLRP3 inflammasome innate immune pathway","volume":"82","author":"Kode","year":"2022","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.116432_bb0545","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.7150\/ijbs.93943","article-title":"Coenzyme Q(0) inhibited the NLRP3 inflammasome, metastasis\/EMT, and Warburg effect by suppressing hypoxia-induced HIF-1\u03b1 expression in HNSCC cells","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"8_Supplement_1","key":"10.1016\/j.intimp.2026.116432_bb0550","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1538-7445.AM2025-3052","article-title":"Abstract 3052: butyrate reduces NLRP3 RNA expression in oral squamous cell carcinoma","volume":"85","author":"Loperena Gonzalez","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116432_bb0555","first-page":"302","article-title":"Empagliflozin inhibits OSCC proliferation and migration by suppressing SLC2A3 and NLRP3","volume":"13","author":"Tezcan","year":"2025","journal-title":"Nam\u0131k Kemal Med. J."},{"issue":"2","key":"10.1016\/j.intimp.2026.116432_bb0560","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/0113892029284920240212091903","article-title":"Expression profiling of EMT transcriptional regulators ZEB1 and ZEB2 in different histopathological grades of oral squamous cell carcinoma patients","volume":"25","author":"Baqai","year":"2024","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.intimp.2026.116432_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107660","article-title":"Alpinetin exerts anti-inflammatory, anti-oxidative and anti-angiogenic effects through activating the Nrf2 pathway and inhibiting NLRP3 pathway in carbon tetrachloride-induced liver fibrosis","volume":"96","author":"Zhu","year":"2021","journal-title":"Int. Immunopharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:04:53Z","timestamp":1774591493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926002766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":113,"alternative-id":["S1567576926002766"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116432","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NLRP3 inflammasome as a therapeutic target in oral squamous cell carcinoma: implications for tumorigenesis and immunomodulation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116432"}}